Pular para o conteúdo principal
Ranking Invest

AKRO - Akero Therapeutics, Inc.

Segmento: HealthcareAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Dados da Empresa

Patrimônio Líquido

$ 1.08 Bi

Dívida Líquida

-$ 178.81 Mi

L4T

-$ 269.44 Mi

Indicadores Básicos

ROE

-24.86%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.21

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

G-10.34

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.16

DIV/L4T

0.66

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.